Analysts Expect AzurRx BioPharma Inc (NASDAQ:AZRX) to Announce -$0.09 Earnings Per Share

Equities research analysts forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will post ($0.09) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for AzurRx BioPharma’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.11). AzurRx BioPharma posted earnings per share of ($0.17) in the same quarter last year, which would suggest a positive year over year growth rate of 47.1%. The company is expected to announce its next quarterly earnings report on Thursday, November 12th.

According to Zacks, analysts expect that AzurRx BioPharma will report full-year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.64) to ($0.40). For the next year, analysts anticipate that the firm will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.42) to ($0.29). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for AzurRx BioPharma.

Separately, Maxim Group reiterated a “buy” rating and set a $3.00 price objective on shares of AzurRx BioPharma in a research note on Thursday, August 13th.

AZRX stock traded down $0.02 during trading on Friday, hitting $0.70. 148,854 shares of the company’s stock traded hands, compared to its average volume of 388,199. AzurRx BioPharma has a 1 year low of $0.37 and a 1 year high of $1.94. The business has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $0.80.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Read More: Blockchain

Get a free copy of the Zacks research report on AzurRx BioPharma (AZRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AzurRx BioPharma (NASDAQ:AZRX)

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.